Treatment Decision-Making for Individuals with Relapsed/Refractory Chronic Lymphocytic Leukemia in the USA
Acta Haematologica · 07.05.2026 · 1-14
DOI: 10.1159/000552243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 07.05.2026. Verfasst von Catherine C Coombs und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of California Irvine School of Medicine, Irvine, California, USA. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Introduction
As available treatment options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) increase, treatment decisions become increasingly complex. This cross-sectional study evaluated patient and physician decision-making when selecting treatment for R/R CLL in the USA.
Methods
After an initial pilot, 100 individuals with R/R CLL and 100 physicians who treat R/R CLL completed web-based surveys on factors that influenced treatment selection and levels of involvement during treatment selection. Categorical measures were summarized using numbers/proportions, and continuous measures were summarized using means/standard deviations.
Results
Individuals with R/R CLL and physicians prioritized treatment efficacy (individuals: N = 47 of 78, 60.3%; physicians: N = 79 of 100, 79.0%) and potential side effects (individuals: N = 43 of 78, 55.1%; physicians: N = 50 of 79, 63.3%) when selecting treatment. Differences in the relative importance of specific factors were observed. Financial and cost factors were important for individuals, while medical history was important for physicians. Both cohorts reported a shared decision-making process.
Conclusion
Building upon previous findings in the front-line CLL setting, this study confirms that individuals with R/R CLL and physicians commonly consider efficacy and safety of different treatment options when making their decision. Relative importance of specific factors within these and other categories differs across the samples.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California Irvine School of Medicine, Irvine, California, USA.
- Duke University School of Medicine, Durham, North Carolina, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Analysis Group Inc., Boston, Massachusetts, USA, urvi.desai@analysisgroup.com.
- Analysis Group Inc., Boston, Massachusetts, USA.
- CLL Society, Chula Vista, California, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Coombs, C. C., LeBlanc, T. W., Winfree, K. B., Muehlenbein, C. E., Desai, U., Kirson, N. Y., Holub, A., Qu, A., Sears, E., Koffman, B., & Thompson, M. C. (2026). Treatment Decision-Making for Individuals with Relapsed/Refractory Chronic Lymphocytic Leukemia in the USA. Acta Haematologica, 1-14. https://doi.org/10.1159/000552243
Vancouver
Coombs CC, LeBlanc TW, Winfree KB, Muehlenbein CE, Desai U, Kirson NY, et al. Treatment Decision-Making for Individuals with Relapsed/Refractory Chronic Lymphocytic Leukemia in the USA. Acta Haematologica. 2026:1-14. doi:10.1159/000552243
BibTeX
@article{Coombs2026,
author = {Coombs, Catherine C and LeBlanc, Thomas W and Winfree, Katherine B and Muehlenbein, Catherine E and Desai, Urvi and Kirson, Noam Y and Holub, Ashley and Qu, Alice and Sears, Ellen and Koffman, Brian and Thompson, Meghan C},
title = {Treatment Decision-Making for Individuals with Relapsed/Refractory Chronic Lymphocytic Leukemia in the USA},
journal = {Acta Haematologica},
year = {2026},
pages = {1--14},
doi = {10.1159/000552243}
}
EUVIMED